STRIVERDI RESPIMAT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for STRIVERDI RESPIMAT (STRIVERDI RESPIMAT).
Olodaterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP levels in bronchial smooth muscle, leading to bronchodilation.
| Metabolism | Primarily metabolized by direct glucuronidation via UGT2B7 and to a lesser extent by UGT1A1, 1A7, 1A9; also O-demethylation via CYP2C8 and CYP2C9 followed by conjugation; substrate for CYP2C8, CYP2C9, and UGTs. |
| Excretion | After intravenous administration of olodaterol, approximately 38% of the dose is excreted in urine (including 19% as unchanged drug) and 53% in feces (including 7% as unchanged drug). After inhalation, renal excretion of unchanged olodaterol accounts for about 5-7% of the dose. |
| Half-life | Terminal elimination half-life is approximately 45 hours (range 30-60 hours). This long half-life supports once-daily dosing. Steady-state is reached after 8 days of once-daily inhalation. |
| Protein binding | Approximately 60% bound to human plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution at steady state (Vss) after intravenous administration is approximately 200-300 L, indicating extensive tissue distribution. Vd/F after inhalation is approximately 1400 L. |
| Bioavailability | Absolute bioavailability after inhalation via Respimat is about 30% of the nominal dose. Oral bioavailability is low (less than 1%) due to extensive first-pass metabolism. |
| Onset of Action | Bronchodilation occurs within 5 minutes after inhalation of Striverdi Respimat, with clinically meaningful improvement seen at 5 minutes. |
| Duration of Action | Bronchodilation is maintained for 24 hours after a single dose, allowing once-daily dosing. The trough FEV1 remains significantly above placebo at 24 hours. |
2.5 mcg (two inhalations) once daily via Respimat inhaler; maximum dose 5 mcg (two inhalations) once daily.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment required; use with caution due to potential for anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for STRIVERDI RESPIMAT (STRIVERDI RESPIMAT).
| Breastfeeding | Not known if excreted in human milk. M/P ratio: not established. Caution: due to potential for beta-2 agonist effects in infant, decision to discontinue nursing or drug based on importance to mother. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, inhaled beta-2 agonists caused adverse effects (cleft palate, delayed ossification) at high systemic exposures. No adequate human studies; risk cannot be ruled out. Use only if benefit outweighs risk, especially in first trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to olodaterol or any component of the formulation."]
| Precautions | ["Paradoxical bronchospasm may occur with life-threatening consequences; discontinue immediately if occurs.","Cardiovascular effects: Use caution in patients with cardiovascular disorders, especially coronary insufficiency, arrhythmias, hypertension, and those with convulsive disorders or thyrotoxicosis.","Do not use as rescue therapy for acute deterioration of COPD.","Beta-adrenergic agonists may produce hypokalemia and hyperglycemia; monitor serum potassium and glucose in susceptible patients.","Immediate hypersensitivity reactions may occur."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal pulmonary function, heart rate, blood pressure, serum potassium (risk of hypokalemia). Fetal: assess growth and well-being via ultrasound if prolonged use; watch for maternal hyperglycemia. |
| Fertility Effects | No human data on fertility. Animal studies: no impairment at doses up to 1.8 mg/kg/day (approx. 120x MRHD in rats). Beta-2 agonists may theoretically affect uterine contractility; no evidence of fertility disruption. |